Biogen to invest further $2bn in North Carolina's Research Triangle Park
The latest manufacturing investment will support the ongoing development of Biogen's late-stage clinical pipeline.
Since its establishment in 1995, the company's manufacturing in RTP has been crucial in providing innovative treatments to millions of patients globally.
The company has invested $10bn in its North Carolina manufacturing, and plans to enhance its investments in various modalities and facilities at its two campuses in RTP.
These funds will involve expanding its antisense oligonucleotide (ASO) capabilities and infrastructure, developing multi-platform fill-finish capabilities for clinical and commercial use, and further modernising manufacturing technologies and controls through AI and advanced automation.
Biogen pharmaceutical operations and technology head Nicole Murphy stated: 'We are proud of our longstanding commitment to manufacturing innovation, investment and collaboration with the Research Triangle Park community.
'Our manufacturing footprint in the US has played a critical role in Biogen's history and success, and in advancing the treatments that are making an impact for patients, families and communities here in the US and around the world.
'With this investment, we will modernise and expand our manufacturing capability to enable our pipeline and provide resilient patient supply, while continuing to support the skilled and dedicated community of life sciences talent in North Carolina.'
More than 90% of the advanced commercial medicines developed by Biogen undergo manufacturing and quality control testing in the US.
In May 2025, Biogen and City Therapeutics collaborated to develop RNA interference (RNAi) therapy.
Biogen agreed to pay City Therapeutics $46m: $16m upfront and $30m investment in the form of a convertible note.
"Biogen to invest further $2bn in North Carolina's Research Triangle Park" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 hours ago
- Yahoo
Alnylam Pharmaceuticals, Inc. (ALNY) Gets EU Nod for AMVUTTRA
We recently compiled a list of Alnylam Pharmaceuticals, Inc. stands eighth on our list and recently got approval for AMVUTTRA. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a leading biopharmaceutical company specializing in RNA interference (RNAi) therapeutics, with four FDA-approved drugs for rare genetic diseases. Recently, the company has made significant strides in treating transthyretin amyloidosis (ATTR), a progressive disease affecting the heart and nerves. In March 2025, the FDA approved AMVUTTRA (vutrisiran) to reduce cardiovascular death and hospitalizations in ATTR-CM patients, based on strong results from the HELIOS-B Phase 3 trial. The drug also received approval from the European Commission in June 2025. Long-term data (up to 42 months) continues to support its effectiveness in improving heart function and quality of life. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), considered one of the most undervalued stocks in the biotech sector, is advancing nucresiran (ALN-TTRsc04), a next-gen RNAi treatment for ATTR. Interim Phase 1 results show sustained TTR protein reduction (over 90% within 15 days), with potential for once- or twice-yearly dosing. The drug enters Phase 3 trials in 2025 through the TRITON-CM program, aiming for longer-lasting, more convenient treatment options. A close-up of a staff member counting pills in a pharmaceutical warehouse. Beyond ATTR, the business is expanding its pipeline with nine new investigational therapies by the end of 2025, including treatments for Huntington's disease, bleeding disorders, and type 2 diabetes. The company also initiated a landmark Phase 1 trial for ALN-HTT02 in Huntington's, marking its entry into neurotherapeutics. Platform upgrades are targeting improved delivery to organs like the brain, heart, and kidneys, enhancing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)'s ability to address both rare and common diseases. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
2 days ago
- Medscape
EMA OKs Oral Treatment for Postnatal Depression
The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has adopted a positive opinion on zuranolone (Zurzuvae, Biogen Netherlands BV), the first oral drug to treat postpartum depression in adults. Marketing authorization was granted in recognition of clinical trial results showing a reduction in postpartum depressive symptoms after 2 weeks' treatment. Zuranolone is a neuroactive steroid that enhances the activity of the neurotransmitter gamma-aminobutyric acid (GABA). It is thought to exert antidepressant effects by enhancing GABAergic inhibition. In a multicenter, randomized, double-blind, placebo-controlled study, zuranolone at a 50 mg dose was given for 14 days to women who met the Diagnostic and Statistical Manual of Mental Disorders criteria for a major depressive episode of postpartum depression and whose symptoms started in the third trimester or within 4 weeks of delivery. Compared with placebo, the active group demonstrated significantly greater symptom improvement on days 3,15 (the primary endpoint), and 45, using the standard 17-item Hamilton rating scale for depression. The FDA approved the drug in August 2023, at which time it was the first oral treatment for postpartum depression, with previous therapies requiring intravenous dosing. It is available in 20 mg, 25 mg, and 30 mg capsules. The most common side effects are somnolence, dizziness, confusion, trouble walking, and sedation. Patients are advised to avoid alcohol and not to drive, operate machinery, or undertake other dangerous activities until at least 12 hours after taking each dose during the 14-day treatment course. There may also be an increased risk of suicidal thoughts and actions in people 24 years of age and younger. Animal studies have suggested a possible risk of teratogenic effects, so women who may become pregnant are advised to use effective contraception during treatment and for 1 week after the final dose, and to alert their healthcare provider should they become pregnant during treatment. The EMA said that detailed recommendations will be described in the summary of product characteristics, which will be published on the EMA website in all official European Union languages after the marketing authorization has been granted by the European Commission. Perinatal Mental Healthcare 'in Its Infancy' In Western countries, postpartum depression is estimated to affect between 10% and 15% of women during the first year after birth , with substantial differences in rates depending on socioeconomic factors such as marital status, educational level, social support, spouse care, violence, gestational age, breast feeding, child mortality, financial difficulties, partnership, life stress, smoking, alcohol intake, and living conditions. Common symptoms include feelings of desperation, sadness, anxiety, irritability, and isolation, as well as nausea, changes in sleep and eating habits, decreased libido, crying spells, mental lability, thoughts of hurting oneself and/or the infant, and suicidal ideation. The condition can wreak havoc on women's mental health as well as that of their partners. It can impair the parental relationship, the mother-child bond, and the emotional and cognitive growth of infants, with potential long-term effects. Postnatal depression may occur alongside post-traumatic stress disorder following stressful or traumatic childbirth experiences . Yet a review published in Frontiers in Psychiatry last year suggested that fewer than half of countries in the World Health Organization (WHO) European region had policies specifically on perinatal mental health, leading its authors to conclude that "perinatal mental health care is in its infancy in most WHO European countries."
Yahoo
6 days ago
- Yahoo
Biogen to invest further $2bn in North Carolina's Research Triangle Park
Biogen has announced plans to invest an additional $2bn in Research Triangle Park (RTP) in the US state of North Carolina. The latest manufacturing investment will support the ongoing development of Biogen's late-stage clinical pipeline. Since its establishment in 1995, the company's manufacturing in RTP has been crucial in providing innovative treatments to millions of patients globally. The company has invested $10bn in its North Carolina manufacturing, and plans to enhance its investments in various modalities and facilities at its two campuses in RTP. These funds will involve expanding its antisense oligonucleotide (ASO) capabilities and infrastructure, developing multi-platform fill-finish capabilities for clinical and commercial use, and further modernising manufacturing technologies and controls through AI and advanced automation. Biogen pharmaceutical operations and technology head Nicole Murphy stated: 'We are proud of our longstanding commitment to manufacturing innovation, investment and collaboration with the Research Triangle Park community. 'Our manufacturing footprint in the US has played a critical role in Biogen's history and success, and in advancing the treatments that are making an impact for patients, families and communities here in the US and around the world. 'With this investment, we will modernise and expand our manufacturing capability to enable our pipeline and provide resilient patient supply, while continuing to support the skilled and dedicated community of life sciences talent in North Carolina.' More than 90% of the advanced commercial medicines developed by Biogen undergo manufacturing and quality control testing in the US. In May 2025, Biogen and City Therapeutics collaborated to develop RNA interference (RNAi) therapy. Biogen agreed to pay City Therapeutics $46m: $16m upfront and $30m investment in the form of a convertible note. "Biogen to invest further $2bn in North Carolina's Research Triangle Park" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
